Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was $1.49 for the day, down -4.49% from the previous closing price of $1.56. In other words, the price has decreased by -$4.49 from its previous closing price. On the day, 0.8 million shares were traded. ZNTL stock price reached its highest trading level at $1.57 during the session, while it also had its lowest trading level at $1.49.
Ratios:
Our analysis of ZNTL’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.99 and its Current Ratio is at 7.99. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.
Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 107481832 and an Enterprise Value of -154632176. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.00 while its Price-to-Book (P/B) ratio in mrq is 0.39. Its current Enterprise Value per Revenue stands at -5.756 whereas that against EBITDA is 0.908.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.85, which has changed by -0.534375 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $4.44, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -6.79%, while the 200-Day Moving Average is calculated to be -9.97%.
Shares Statistics:
ZNTL traded an average of 710.01K shares per day over the past three months and 819500 shares per day over the past ten days. A total of 72.14M shares are outstanding, with a floating share count of 58.17M. Insiders hold about 19.37% of the company’s shares, while institutions hold 69.76% stake in the company. Shares short for ZNTL as of 1759190400 were 4415449 with a Short Ratio of 6.22, compared to 1756425600 on 4484034. Therefore, it implies a Short% of Shares Outstanding of 4415449 and a Short% of Float of 7.64.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.27 and low estimates of -$0.61.
Analysts are recommending an EPS of between -$1.48 and -$2.13 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.84, with 7.0 analysts recommending between -$1.15 and -$2.28.
